Research Studies

Children’s Autism Metabolome Project (CAMP)

The Children’s Autism Metabolome Project (CAMP) was the largest study to date to evaluate the metabolism of children with autism spectrum disorder (ASD).

  • 1,100 children enrolled
  • 18-48 months old
  • 8 clinical study sites, including some of the leading autism centers in the country
  • Consisted of behavioral evaluation and a fasting blood plasma sample.
  • Compared the metabolic results to the behavioral evaluation to identify differences in metabolism of children who were diagnosed with ASD.
  • Validated the NPDX AA test, a tool that may lead to an earlier autism spectrum disorder diagnosis for some children

We are grateful to all of the children and families who participated in the CAMP clinical study. They took the time and trouble to help us better understand ASD and develop the NPDX AA test, which has the potential to help kids receive an earlier ASD diagnosis and more precise treatment. Thank you!

CAMP Clinical Sites

UC-Davis MIND Institute
Dr. David Amaral – Principal Investigator

Nationwide Children’s Hospital
Dr. Daniel Coury – Principal Investigator

Massachusetts General Hospital
Lurie Center for Autism
Dr. Ann Neumeyer – Principal Investigator

Melmed Center
Dr. Raun Melmed – Principal Investigator

Monroe Carell, Jr. Children’s Hospital at Vanderbilt
Dr. Kevin Sanders – Principal Investigator
Dr. Allyson Cundiff – Principal Investigator

Children’s Hospital of Philadelphia (CHOP)
Dr. Amanda Bennett-Palladino – Principal Investigator

Arkansas Children’s Research Hospital
Dr. Richard Frye – Principal Investigator

Cincinnati Children’s Hospital Medical Center
Dr. Logan Wink – Principal Investigator

This study was funded by a grant from the National Institutes of Mental Health and investments by the Nancy Lurie Marks Family Foundation and the Robert E. and Donna Landreth Family Fund.

CAMP is the largest of NeuroPointDX’s studies of autism spectrum disorder and metabolism, but it wasn’t the only research we conducted.

Learn more about our earlier studies >>

Read the paper that details the results of CAMP.1

Reference

  1. Smith, A., et al., Amino acid dysregulation metabotypes: potential biomarkers for diagnosis and individualized treatment for subtypes of autism spectrum disorder. 2018 Biological Psychiatry, doi: 10.1016/j.biopsych.2018.08.016.